5th Pulmonary Medicine Department, SOTIRIA Thoracic Diseases Hospital of Athens, 11527 Athens, Greece.
2nd Pulmonary Medicine Department, General University Hospital "Attikon", Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Adv Respir Med. 2024 Nov 6;92(6):466-471. doi: 10.3390/arm92060042.
: Depression and anxiety represent significant comorbidities in idiopathic pulmonary fibrosis (IPF) patients, affecting their quality of life. The COVID-19 pandemic has had an uneven impact on global mental health. The Hospital Anxiety and Depression Scale (HADS) constitutes a validated tool to identify anxiety disorders and depression. The aim of this multicentre study was to evaluate the effect of COVID-19 vaccination on depression and anxiety in IPF patients. : Consecutive IPF patients (median 73.5 years) who are regularly followed-up with were included in the study. Demographics, functional, and clinical were recorded. The HADS score was calculated before and one month after vaccination against COVID-19 in all participants. A Wilcoxon signed ranks test was conducted. : A total of 180 IPF patients (median 73.5 years) were included in the study. Among them, 145 patients (81%) received antifibrotic treatment. A significant reduction in HADS, both in anxiety and depression scales, was observed one month after vaccination against SARS-COV-2), independent of age, smoking, lung function impairment, and prior history of depression ( < 0.01). : A higher Hospital Anxiety and Depression Scale score was detected before vaccination against COVID-19. It seems that vaccination also offered a beneficial effect on depression and anxiety in IPF patients, independent of age, smoking, lung function impairment, and prior history of depression.
: 抑郁和焦虑是特发性肺纤维化 (IPF) 患者的常见合并症，影响其生活质量。COVID-19 大流行对全球心理健康产生了不均衡的影响。医院焦虑和抑郁量表 (HADS) 是一种用于识别焦虑症和抑郁症的有效工具。本多中心研究的目的是评估 COVID-19 疫苗接种对 IPF 患者抑郁和焦虑的影响。 : 研究纳入了定期随访的连续 IPF 患者（中位数年龄 73.5 岁）。记录了人口统计学、功能和临床数据。所有参与者在接种 COVID-19 疫苗前后均计算了 HADS 评分。采用 Wilcoxon 符号秩检验进行分析。 : 共纳入 180 例 IPF 患者（中位数年龄 73.5 岁）。其中，145 例（81%）接受了抗纤维化治疗。接种 SARS-COV-2 疫苗一个月后，HADS 在焦虑和抑郁量表上均显著降低，与年龄、吸烟、肺功能损害和既往抑郁史无关（<0.01）。 : 接种 COVID-19 疫苗前 HADS 评分较高。接种疫苗似乎对 IPF 患者的抑郁和焦虑也有有益的影响，与年龄、吸烟、肺功能损害和既往抑郁史无关。
